Remove Clinical Trials Remove Therapies Remove Treatment
article thumbnail

Novel stem cell therapy repairs 'irreversible' corneal damage in clinical trial

Science Daily: Pharmacology News

Results from a phase 1/2 clinical trial of a novel stem cell treatment for cornea injuries found 14 patients treated and tracked for 18 months had a more than 90% success rate at restoring the cornea's surface and improvements in vision.

article thumbnail

Trial Confirms 'Life-Changing' Impact of Gene Therapy, Beqvez, for Hemophilia B

Drugs.com

25, 2024 -- A new gene therapy approved earlier this year can serve as a sustainable single-dose treatment for people with hemophilia B, newly published clinical trial data shows. THURSDAY, Sept. People with hemophilia B saw their bleeding episodes.

Therapies 290
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

At-Home Brain Stimulation Treatment Can Safely Ease Depression

Drugs.com

22, 2024 -- At-home brain stimulation therapy can safely and effectively treat severe to moderate depression, a new clinical trial shows.Rates of treatment response and depression remission were three times higher in people receiving. TUESDAY, Oct.

Treatment 279
article thumbnail

FDA panel votes against MDMA therapy for PTSD, citing muddy data and safety concerns

BioPharma Drive: Drug Pricing

A group of independent experts wasn't convinced by clinical trial data from company Lykos Therapeutics, which is seeking FDA approval of MDMA-assisted treatment for post-traumatic stress disorder.

FDA 329
article thumbnail

Trial Confirms 'Life-Changing' Impact of Gene Therapy for Hemophilia B

Drugs.com

25, 2024 -- A new gene therapy approved earlier this year can serve as a sustainable single-dose treatment for people with hemophilia B, newly published clinical trial data shows.People with hemophilia B saw their bleeding episodes. THURSDAY, Sept.

Therapies 246
article thumbnail

New cell therapy model accelerates cancer treatment development

Drug Target Review

In the rapidly advancing field of cell therapies, Dr Jason Bock has emerged as a leader, known for his innovative approach to optimising the development process. With over 25 years of experience in therapeutics, Bock has played a pivotal role in shaping the future of cell therapies, particularly through his work at CTMC.

article thumbnail

Children surpass a year of HIV remission after treatment pause

Science Daily: Pharmacology News

Four children have remained free of detectable HIV for more than one year after their antiretroviral therapy (ART) was paused to see if they could achieve HIV remission, according to new research.

Treatment 318